Drugs List

Therapeutic Indications

Uses

Eye - non-infected inflammatory conditions

Contraindications

Glaucoma
Ocular infection

Precautions and Warnings

Infants
Breastfeeding
Pregnancy

Advise patient blurred vision may affect ability to drive/operate machinery
Treat and control infections prior to commencing therapy
In combined therapy, administer eye products at least five minutes apart
To reduce systemic absorption compress lacrimal sac during administration
Check ocular lens frequently - risk of cataract formation
Monitor intraocular pressure frequently - risk of steroid glaucoma
Perform eye tests in any patient with vision change/ophthalmologic symptoms
Prolonged or high dose may lead to adrenal suppression
Contains phosphate: Risk of calcification in existing notable cornea damage
Systemic side effects may occur
Withdraw gradually after long-term use

There is an increased risk of adrenal suppression in infants, particularly after prolonged use. In addition, systemic effects may include growth retardation, psychological and behavioural effects in children and adolescents.

Pregnancy and Lactation

Pregnancy

Use prednisolone sodium phosphate preservative-free eye drops with precaution during pregnancy.

The manufacturer recommends prednisolone sodium phosphate preservative-free eye drops should be avoided during pregnancy. Animals studies show that topical administration of corticosteroids can cause abnormalities of foetal development, including cleft palate and intrauterine growth retardation. At the time of writing there is limited human data available. There may be a small risk of similar effects in the human foetus.

Lactation

Use prednisolone sodium phosphate preservative-free eye drops with caution during breastfeeding.

There is insufficient information on the excretion of prednisolone sodium phosphate and its metabolites in human milk. Effects on exposed infants are unknown.

Side Effects

Adrenal suppression
Blurred vision
Cataracts
Increased intra-ocular pressure

Presentation

Preservative free eye drops containing prednisolone sodium phosphate.

Drugs List

Therapeutic Indications

Uses

Eye - non-infected inflammatory conditions

Dosage

Adults

Children

Contraindications

Glaucoma
Ocular infection

Precautions and Warnings

Infants
Breastfeeding
Pregnancy

Advise patient blurred vision may affect ability to drive/operate machinery
Treat and control infections prior to commencing therapy
In combined therapy, administer eye products at least five minutes apart
To reduce systemic absorption compress lacrimal sac during administration
Check ocular lens frequently - risk of cataract formation
Monitor intraocular pressure frequently - risk of steroid glaucoma
Perform eye tests in any patient with vision change/ophthalmologic symptoms
Prolonged or high dose may lead to adrenal suppression
Contains phosphate: Risk of calcification in existing notable cornea damage
Systemic side effects may occur
Withdraw gradually after long-term use

There is an increased risk of adrenal suppression in infants, particularly after prolonged use. In addition, systemic effects may include growth retardation, psychological and behavioural effects in children and adolescents.

Pregnancy and Lactation

Pregnancy

Use prednisolone sodium phosphate preservative-free eye drops with precaution during pregnancy.

The manufacturer recommends prednisolone sodium phosphate preservative-free eye drops should be avoided during pregnancy. Animals studies show that topical administration of corticosteroids can cause abnormalities of foetal development, including cleft palate and intrauterine growth retardation. At the time of writing there is limited human data available. There may be a small risk of similar effects in the human foetus.

Lactation

Use prednisolone sodium phosphate preservative-free eye drops with caution during breastfeeding.

There is insufficient information on the excretion of prednisolone sodium phosphate and its metabolites in human milk. Effects on exposed infants are unknown.

Side Effects

Adrenal suppression
Blurred vision
Cataracts
Increased intra-ocular pressure

Overdosage

It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

The following number will direct the caller to the relevant local centre (0844) 892 0111

Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Further Information

Last Full Review Date: October 2019

Reference Sources

Summary of Product Characteristics: Minims Prednisolone Sodium Phosphate 0.5% w/v, Eye drops solution. Bausch & Lomb U.K. Limited. Revised May 2017.